Zydus Cadila unveils pressurized Metered Dose Inhaler for COPD patients in India

COPD is the third leading cause of death worldwide and in India an estimated 55.3 million patients suffer from COPD.

Speaking on the development, Managing Director, Cadila Healthcare Ltd., Dr. Sharvil Patel said, "Our focus has always been on helping people lead a better quality of life and making therapies accessible and affordable to people. Our innovations have brought in next-generation therapies in respiratory, women's healthcare, cardio-metabolic disorders, gastrointestinal and pain management segments. With this new technology, we hope to bring much relief to patients suffering from COPD and help them improve their health and quality of life."

The novel process for Forglyn pMDI developed at the group's Pharmaceutical Technology Center, ensures that delivery of the two drugs administered simultaneously through the inhaler are consistent and uniform which is critical for inhalation products.

The process technology employed for the manufacturing of this product is simple, affordable and scalable. The Company has also filed a patent application for the novel process of this product.